Creating Consistent Value in Biotech Without Diluting Stakeholders
One of the greatest challenges for pre-commercial biotech companies is consistently generating capital necessary for operating costs and for R&D of new products that provide value to stakeholders, both for investors and patients. At OSE Immunotherapeutics we implemented a business model that allows us to be one of the rare French biotech companies without commercial products able to generate revenue and advance multiple clinical stage assets without needing dilutive funding since our 2015 IPO.
Cue Biopharma Pioneers In Vivo T-Cell Enhancement
Cue Biopharma has quickly evolved into a player in the T-cell space. The company was formed in 2015, a spin-out from the Albert Einstein College of Medicine. Dan Passeri, the company CEO, has a background in oncology drug development and has worked at the National Cancer Institute. When he was asked to take over the firm in August 2016, he was employee number eight.
Why Soon-Shiong Thinks His Triangle Offense for Cancer Can Be Applied to COVID-19
Patrick Soon-Shiong likes to talk about the “triangle offense,” the activation of a combination of macrophages, natural killer cells, and memory T-cells to battle cancer. He believes the same approach he has been working to train on cancer can be enlisted in the fight against COVID-19, the virus behind today’s global pandemic. We spoke to Soon-Shiong, chairman and CEO of NantKwest, about his approach to immunotherapy, what results he’s seen to date, and why he believes what he’s learned about harnessing the immune system in the fight against cancer can be applied to treating COVID-19.
Contagion Connect Episode 7 – The ID Pipeline: Rezafungin & Antiviral Fc-Conjugates
Cidara Therapeutics is developing a new echinocandin called Rezafungin that’s shown promise in clinical trials. Cidara is also developing a new anti-viral technology which isn’t a vaccine, but could provide universal flu protection on a different basis.
Empowered by Parkinson’s
Empowered by Parkinson’s premieres on Wednesday, April 1, 2020 at 10 p.m. on CPTV. It encores on Saturday, April 11, 2020 at 7 p.m. on CPTV and Tuesday, April 21, 2020 at 10 p.m. on CPTV.
OSE Immunotherapeutics Meets Primary Endpoint in Phase III Trial for HLA-A2 Positive Lung Cancer
In Step 1 of the Phase III Atalante 1 trial, OSE Immunotherapeutics’ investigational agent Tedopi improved the 12-month survival rate over chemotherapy in patients with HLA-A2 positive non-small cell lung cancer who faile
Biotech Startups Hoping to ‘Thrive’ Amid Coronavirus Chaos
Not long ago biotechnology entrepreneurs expected 2020 to be another flush year for their industry, with funds flowing into startups pursuing new medicines for cancer, rare diseases and other illnesses.
Critical Colonoscopy Advancements Impact Results and Costs with Tim Moran Motus GI
Tim Moran, CEO, Motus GI talks about their focus on endoscopy solutions that improve clinical outcomes for patients facing a critical colonoscopy while in the hospital. The Pure-Vu system developed by Motus GI is a disposable sleeve that fits on the top of their reusable scope to allow irrigation and suction evacuation. This enhancement can save time by eliminating delays in conducting the colonoscopy as well as reducing costs and need for additional time in the hospital.
